Literature DB >> 12133662

Postexposure prophylaxis against prion disease with a stimulator of innate immunity.

Shneh Sethi1, Grayson Lipford, Hermann Wagner, Hans Kretzschmar.   

Abstract

The absence of an immune response to prions--the infectious agents of scrapie, bovine spongiform encephalopathy (BSE), and Creutzfeldt-Jakob disease--might be related to the fact that these agents do not contain nucleic acids. We aimed to use CpG oligodeoxynucleotides, which have been shown to stimulate innate immunity, as a form of postexposure prophylaxis in mice. We inoculated healthy mice with brain homogenates from mice infected with the RML scrapie prion, and then injected CpG oligodeoxynucleotides. This postexposure prophylaxis with CpG oligodeoxynucleotides resulted in 38% longer survival times than treatment with saline (p<0.0001), or even longer after repeated application. The explanation for this finding remains to be elucidated, but the most likely is stimulation of TLR9-expressing cells of the innate immune system such as macrophages, monocytes, and dendritic cells. CpG oligodeoxynucleotides have not been shown to have adverse effects to human health and could therefore be considered as a therapeutic choice in postexposure prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12133662     DOI: 10.1016/S0140-6736(02)09513-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  34 in total

Review 1.  Microglia in prion diseases.

Authors:  Adriano Aguzzi; Caihong Zhu
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

2.  Phosphorothioate oligonucleotides reduce PrP levels and prion infectivity in cultured cells.

Authors:  Marcela V Karpuj; Kurt Giles; Sagit Gelibter-Niv; Michael R Scott; Vishwanath R Lingappa; Francis C Szoka; David Peretz; Wilfred Denetclaw; Stanley B Prusiner
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

3.  Protective role of interferon regulatory factor 3-mediated signaling against prion infection.

Authors:  Daisuke Ishibashi; Ryuichiro Atarashi; Takayuki Fuse; Takehiro Nakagaki; Naohiro Yamaguchi; Katsuya Satoh; Kenya Honda; Noriyuki Nishida
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 4.  Developing Therapeutics for PrP Prion Diseases.

Authors:  Kurt Giles; Steven H Olson; Stanley B Prusiner
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

5.  Progress and problems in the biology, diagnostics, and therapeutics of prion diseases.

Authors:  Adriano Aguzzi; Mathias Heikenwalder; Gino Miele
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

6.  Scrapie protein degradation by cysteine proteases in CD11c+ dendritic cells and GT1-1 neuronal cells.

Authors:  Katarina M Luhr; Elin K Nordström; Peter Löw; Hans-Gustaf Ljunggren; Albert Taraboulos; Krister Kristensson
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 7.  Toll-like receptors expression and signaling in glia cells in neuro-amyloidogenic diseases: towards future therapeutic application.

Authors:  Dorit Trudler; Dorit Farfara; Dan Frenkel
Journal:  Mediators Inflamm       Date:  2010-07-25       Impact factor: 4.711

8.  Binding of recombinant but not endogenous prion protein to DNA causes DNA internalization and expression in mammalian cells.

Authors:  Shaoman Yin; Xingjun Fan; Shuiliang Yu; Chaoyang Li; Man-Sun Sy
Journal:  J Biol Chem       Date:  2008-07-11       Impact factor: 5.157

9.  Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation.

Authors:  Véronique Perrier; Jérôme Solassol; Carole Crozet; Yveline Frobert; Chantal Mourton-Gilles; Jacques Grassi; Sylvain Lehmann
Journal:  J Neurochem       Date:  2004-04       Impact factor: 5.372

10.  Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides.

Authors:  David A Kocisko; Andrew Vaillant; Kil Sun Lee; Kevin M Arnold; Nadine Bertholet; Richard E Race; Emily A Olsen; Jean-Marc Juteau; Byron Caughey
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.